COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
- DOI
- 10.2217/fon-2022-1258
- Published
- 2023 May
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2217/fon-2022-1258,
title = {COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.},
author = {Dummer R and Flaherty KT and Robert C and Arance A and B de Groot JW and Garbe C and Gogas HJ and Gutzmer R and Krajsová I and Liszkay G and Loquai C and Mandalà M and Schadendorf D and Yamazaki N and Pietro AD and Cantey-Kiser J and Edwards M and Ascierto PA},
year = {2023},
journal = {Future oncology (London, England)},
doi = {10.2217/fon-2022-1258},
url = {https://doi.org/10.2217/fon-2022-1258}
}RIS
TY - JOUR TI - COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. AU - Dummer R AU - Flaherty KT AU - Robert C AU - Arance A AU - B de Groot JW AU - Garbe C AU - Gogas HJ AU - Gutzmer R AU - Krajsová I AU - Liszkay G AU - Loquai C AU - Mandalà M AU - Schadendorf D AU - Yamazaki N AU - Pietro AD AU - Cantey-Kiser J AU - Edwards M AU - Ascierto PA PY - 2023 JO - Future oncology (London, England) DO - 10.2217/fon-2022-1258 UR - https://doi.org/10.2217/fon-2022-1258 ER -
APA
R, D., KT, F., C, R., A, A., JW, B. D. G., C, G., HJ, G., R, G., I, K., G, L., C, L., M, M., D, S., N, Y., AD, P., J, C., M, E., & PA, A. (2023). COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.. Future oncology (London, England). https://doi.org/10.2217/fon-2022-1258
Source records
- pubmed · retrieved 2026-09-26T16:42:44.047Z